Clinical Trial Update: Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of the monoclonal antibody MGAH22 (margetuximab) in relapsed or refractory advanced breast cancer has completed, and results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MGAH22 (margetuximab) (margetuximab)

Snippet

Sponsor: MacroGenics | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-09-17